UBS AM
ADMA icon

UBS AM’s ADMA Biologics ADMA Stock Holding History

UBS AM’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31M Buy
395,356
+1,705
+0.4% +$15.5K ﹤0.01% 1819
2026
Q1 		$3.55M Sell
393,651
-6,368
-2% -$100K ﹤0.01% 1745
2025
Q4 		$7.3M Buy
400,019
+9,191
+2% +$155K ﹤0.01% 1275
2025
Q3 		$5.73M Sell
390,828
-552,023
-59% -$9.46M ﹤0.01% 1305
2025
Q2 		$17.2M Buy
942,851
+126,261
+15% +$2.57M ﹤0.01% 1111
2025
Q1 		$16.2M Buy
816,590
+305,064
+60% +$5.28M ﹤0.01% 1042
2024
Q4 		$8.77M Buy
511,526
+1,559
+0.3% +$29.3K ﹤0.01% 1313
2024
Q3 		$10.2M Sell
509,967
-26,020
-5% -$405K ﹤0.01% 1206
2024
Q2 		$5.99M Buy
535,987
+316,700
+144% +$2.66M ﹤0.01% 1393
2024
Q1 		$1.45M Buy
219,287
+32,090
+17% +$175K ﹤0.01% 1835
2023
Q4 		$846K Buy
187,197
+20,569
+12% +$76.1K ﹤0.01% 2117
2023
Q3 		$597K Buy
166,628
+28,500
+21% +$110K ﹤0.01% 2222
2023
Q2 		$457K Hold
138,128
– – ﹤0.01% 2361
2023
Q1 		$457K Buy
+138,128
New +$477K ﹤0.01% 2361

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS AM's ADMA Position: Q2 2026 in Review

UBS AM increased its ADMA Biologics (ADMA) stake by 0.43% in Q2 2026, buying an estimated $15.5K and bringing the position to 395,356 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

UBS AM first reported a position in ADMA in Q1 2023 and has held it in 14 quarters since. The position peaked at $17.2M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • UBS AM held 395,356 shares of ADMA Biologics worth $3.31M as of Q2 2026.
  • UBS AM bought 1,705 ADMA Biologics shares in Q2 2026, an estimated $15.5K.
  • ADMA Biologics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1819 holding.
  • UBS AM first reported a position in ADMA Biologics in Q1 2023 and has held it in 14 quarters since.
  • UBS AM's ADMA Biologics position peaked at $17.2M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.